# Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy

> **NCT04056299** · PHASE2 · TERMINATED · sponsor: **Aimmune Therapeutics, Inc.** · enrollment: 15 (actual)

## Conditions studied

- Hen Egg Allergy

## Interventions

- **BIOLOGICAL:** AR201 powder
- **BIOLOGICAL:** Placebo powder

## Key facts

- **NCT ID:** NCT04056299
- **Lead sponsor:** Aimmune Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-08-20
- **Primary completion:** 2020-12-16
- **Final completion:** 2020-12-28
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** The study was prematurely terminated by the Sponsor based on difficulties in meeting enrollment goals, especially during the COVID-19 pandemic, and not for reasons relating to any concerns regarding quality, safety, or efficacy.
- **Last updated:** 2022-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04056299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04056299, "Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04056299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*